Nectar Lifesciences vs Peers
- Market cap
- ₹201 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹7.44 – ₹13.95
Nectar Lifesciences ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Nectar Lifesciences. Its P/E of 22.5 compares with a peer median of 22.5.
Nectar Lifesciences vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Nectar Lifesciences | 10.33 | -2.46% | 201 | 22.5 | 2.85 | 14.5% | +18.5% |
| Nectar Lifesciences | 10.33 | -2.46% | 201 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Nectar Lifesciences peer comparison — frequently asked questions
Who are Nectar Lifesciences' competitors?
Nectar Lifesciences' listed peers in Drug Manufacturers - Specialty & Generic include Nectar Lifesciences, ranked here by market capitalisation.
How does Nectar Lifesciences' P/E compare with its peers?
Nectar Lifesciences trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Nectar Lifesciences' peers?
By market capitalisation, the largest company in the group is Nectar Lifesciences at ₹201 crore, against ₹201 crore for Nectar Lifesciences.
Same Data For Peers
Trade Nectar Lifesciences With ATS
Track NECLIFE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.